Open Actively Recruiting

SPECT/CT for the Characterization of Renal Masses

About

Brief Summary

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Study Type
Observational
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Performance status Eastern Cooperative Oncology Group (ECOG) < 2.
  • Life expectancy (> 1 year).
  • New diagnosis of a renal tumor (within past 3 months).
  • Measurable, predominantly (> 80%) solid renal neoplasm between 1.5-5.0 cm.
  • Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
  • No definitive evidence of metastatic disease.
  • Does not require urgent surgical treatment.
  • Candidate for surgical, ablative, and surveillance approach.
  • Willingness to obtain more information to aid decision-making.
  • Understanding and willingness to provide consent.

Exclusion Criteria:

  • Presence of multiple solid renal tumors.
  • A prior needle biopsy of the mass resulting in histologic diagnosis.
  • A prior diagnosis of kidney cancer.
  • Presence of an active, untreated, non-renal malignancy.
  • History of bleeding diathesis or recent bleeding episode.
  • Prior surgery or radiation therapy to the kidney.
  • Unwillingness to fill out questionnaires.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-001817
Category
Oncology
Urology
Contact
MARGARET BRADLEY
Location
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
NCT No.
NCT03996850
For detailed technical eligibility, visit ClinicalTrials.gov.